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Summary There is evidence that increased oestrogen receptor (ER) expression in normal mammary epithelium may be a risk markerforthe
development of breast cancer. Insulin-like growth factor 1 (IGF1) is a potent inducer of mitosis and has been shown to synergize with
oestrogen in stimulating the growth of human breast cancer in vitro. In these cells oestradiol has been shown to upregulate IGF type 1
receptor (IGFR), and recently a similar effect has been reported in normal human breast tissue xenografts in vivo. It has been postulated that
the combined effect of oestradiol and IGF1 may stimulate proliferation in normal mammary epithelium and increase breast cancer risk.
The bioavailability of IGF1 to the tissues is modulated by IGF-binding proteins (IGFBPs), and higher circulating levels of IGF1 and lower
levels of IGFBP3 have been reported in breast cancer patients. Breast cancer specimens show a positive correlation between ER status and
IGF receptor status, and also a negative correlation between ER status and IGFBP3 expression. Finally, ectopic growth hormone expression
has been shown in a majority of specimens of normal and malignant breast tissue, and this may contribute to breast cancer risk, possibly by
increasing the local level of bioavailable IGF1. Expansion of such findings may provide clinically useful markers of increased risk to breast
cancer in women.
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Increased oestrogen receptor (ER) expression in normal mammary
epithelium may be a risk marker for the development of breast
cancer (Jacquemier et al, 1990; Ricketts et al, 1991; Khan et al,
1994). ER expression in normal breast tissue is correlated with its
proliferative activity and it has been postulated that the mitogenic
activity ofinsulin-like growth factor 1 (IGF1) might interact with
that ofoestradiol in promoting breast cancerdevelopment afterthe
initiation of carcinogenesis (Clarke et al, 1997). It is useful to
summarize recent studies attempting to correlate measurements of
ER and IGF1 with those of IGFI receptor (IGFR) and binding
proteins (IGFBPs) in human breast cancer and in normal
mammary epithelium.
IGF1, hyperinsulinaemia and breast cancer
A considerable literature has shown that insulin-like growth
factors IGF1 and IGF1 1 can stimulate the growth ofhuman breast
cancer cell lines in vitro (summarized in Westley and May, 1994).
The mitogenic effects of both IGF1 and IGF11 are thought to be
mediated mainly by their binding to the IGF1 receptor, which is
located mainly in the epithelial component ofbreast cancer (Ellis
et al, 1994). Both IGFs are expressed in the stromal component
suggesting that they mainly exert a paracrine effect on the epithe-
lium (Singer et al, 1995) but in addition, circulating IGF1 may
exert an endocrine effect on breast tissue.
It is relevant that hyperinsulinaemia is associated with raised
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bioavailable level ofIGF1 in the tissues by regulating the produc-
tion and proteolysis of IGFBP1 (Holly, 1991). About 25% of the
normal population in Western countries show evidence of hyper-
insulinaemic insulin resistance, and its manifestation is favoured
by ageing, obesity and inadequate exercise (Reaven, 1988).
Case-control studies have shown hyperinsulinaemia to be a risk
marker forbreast cancer (Berstein et al, 1985; Bruning et al, 1992;
Yoshikawa et al, 1994; Tekden et al, 1996). Insulin itself is an
important growth factorinfluencing mammary cancercells in vitro
but its major growth-promoting effect in vivo is likely to be
through IGF1 and IGF1 1.
Case-control studies have shown hyperinsulinaemia to be a risk
marker for cancers of other organs although less significantly so.
These include cancers of the endometrium, bowel, lung and
stomach (Berstein et al, 1985; Copeland et al, 1987; Heslin et al,
1992; Rutanen et al, 1993; Vishnevsky et al, 1993; Yoshikawa et
al, 1994; Yam et al, 1994; Giovanucci, 1995). The association of
hyperinsulinaemia with early stage colorectal cancer (Copeland
et al, 1987) and early stage breast cancer (Bruning et al, 1992)
suggests that it precedes clinical manifestation of the cancer and
does not result from cachexia.
Although substantial data from cell lines, animal models and
primary breast cancer suggest a role for IGF and the IGF receptor
(IGFR) in the control of breast cancer growth, the significance of
an elevated serum level of IGF1 as a risk marker is uncertain.
Published studies variously report moderate elevation in
premenopausal cases (Bruning et al, 1995), marked elevation in
both pre- and post-menopausal cases (Peyrat et al, 1993) and no
association (Favoni et al, 1995). IGF1 is synthesized mainly in the
liver under growth hormone stimulation but it is not stored locally.
Itcirculates as acomplex bound toIGF-bindingproteins (IGFBPs)
and of six IGFBPs identified, IGFBP3 appears to have the main
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role in maintaining the pool of bound IGF1 that responds to
metabolic demand. Recent studies suggest that alterations in
IGFBP3 levels may be more significant in indicating the bio-
availability of IGFl than is the circulating level of IGFl itself
(Frost et al, 1996).
A case-control study reports a decreased serum level of
IGFBP3 to be a risk marker for early breast cancer in
premenopausal Dutch women (Bruning et al, 1996). A decreased
level of IGFBP3 has similarly been reported in the serum of
prostate cancer patients and also in their tumours (Tennant et al,
1996). Decreased serum levels of IGFBP3 are associated with
increased activity of IGFBP3 protease in pregnancy, catabolic
states and after major surgery (Giudice, 1995). It is not clear why
IGFBP3 levels in the serum should be decreased in cancer
patients, but proteolysis of IGFBP3 is regulated by insulin levels
and increased in both adults and children with non-insulin-depen-
dent diabetes mellitus (Giudice, 1995). This might account for
decreased IGFBP3 in a subset ofpatients with cancer ofthe breast
or prostate associated with hyperinsulinaemia.
Interaction between IGF and oestrogen receptors
Studies on breast cancer specimens show a negative correlation
between IGFBP3 expression and oestrogen receptor expression
(McGuire et al, 1994; Yee, 1994; Yu et al, 1995). In addition,
multiple studies show apositive correlation between IGFR and ER
expression (Pekonen et al, 1988; Peyrat et al, 1988; Foekens et al,
1989; Papa et al, 1993; Railo et al, 1994). It has been suggested
that oestrogen stimulates the proliferation ofbreast cancer cells by
regulating pathways distal to the IGFR (Westley and May, 1994).
A recent study on normal human breast tissue xenografts in nude
mice (Clarke et al, 1997) showed that oestradiol caused upregula-
tion ofthe type 1 IGF receptor.
Although ER-positive breast cancers are generally less aggres-
sive than ER-negative tumours, ER expression in normal breast
epithelium may be a risk marker for the development of breast
cancer (Jacquemier et al, 1990; Ricketts et al, 1991; Khan et al,
1994). The odds of finding breast cancer are 6.5 times higher in
mastectomy specimens with an ER-positive epithelium than in
those with an ER-negative epithelium (Khan et al, 1994). A signif-
icant correlation exists between increasing ER positivity and
greater proliferative activity in benign breast lesions (Jacquemier
et al, 1990; Khan et al, 1994), in particular in premenopausal
women. Ductal carcinoma in situ shows ER expression in about
60% of cases, similar to the incidence in invasive breast cancer
(Chaudhari et al, 1993). It has been postulated that an ER-positive
breast epithelium makes the cells susceptible to the mitogenic
effects of oestrogen, whereas an extremely low ER level protects
them (Khan et al, 1994).
Expression of ER in normal breast epithelium is negatively
regulated by oestrogen but ER levels in breast cancer are not
clearly related to the circulating oestrogen levels. A positive corre-
lation has been reported in post-menopausal cases (Drafta et al,
1983) but others find no association between ER level and either
serum or tumour oestradiol level (Markopoulos et al, 1988; Mehta
et al, 1992). European women show a higher rate of ER-positive
breast epithelium than do non-European women (19% vs 4%),
which may result either from dietary factors or from the greater
trend to obesity in the former group (Ricketts et al, 1991). Both
factors are known to influence oestrogen metabolism and this in
turn, may influence ER levels in breast epithelium.
Ageing and obesity increase the rate of ER positivity in breast
cancer just as they increase the incidence of hyperinsulinaemic
insulin resistance. Breast cancers in women below the age of 40
are predominantly ER negative, whereas those in women over the
age of55 are predominantly ER positive (Daniell, 1988). Between
these ages, the proportion ofER-positive tumours depends on both
menopausal status and obesity. Higher rates of ER positivity are
correlated with obesity in most studies but the correlation is more
significant in post-menopausal women (Mehta et al, 1992). Breast
cancer risk is relatively low in Japanese women but in post-
menopausal women the presence of obesity is associated with
ER positivity similar to that seen in western women (Matsumoto,
et al 1986).
Possible role for growth hormone
Human growth hormone (GH) may be involved directly in the
control of mammary growth. Some forms are lactogenic, and in
some experimental animals GH is more potent than prolactin in
stimulating mammary development (Kleinberg et al, 1990). The
treatment of prepubertal girls with isolated GH deficiency by
using recombinant hGH has been shown to accelerate the develop-
ment ofmammary tissue (Darendeliler et al, 1990). A recent study
reports the presence of the gene encoding GH not only in normal
mammary tissue but also in the majority ofbenign and malignant
breast tumours in women (Mol et al, 1995). The researchers postu-
late that mammary cancers may develop autonomous synthesis of
GH. As GH can stimulate mRNA of IGF1 in mammary tissue
(Kleinberg et al, 1990) it is possible that it exerts aparacrine effect
in mammary carcinogenesis by increasing IGF 1 availability
(Feldman et al, 1993). This is in addition to a possible endocrine
effect on bioavailable IGFI levels, because the serum GH level is
correlated with the IGFI/IGFBP3 ratio (Juul et al, 1994).
CONCLUSION
A synergistic effect by oestradiol and IGF1 on the growth of
human breast cancer lines is postulated to result from induction of
IGFR by oestradiol. A recent report ofupregulation oftype 1 IGF
receptor by oestradiol in normal human mammary tissue
xenografts in nude mice (Clarke et al, 1997) provides in vivo
evidence that oestradiol may stimulate proliferation in human
mammary epithelium by a paracrine mechanism involving IGF1.
In addition, circulating IGF1 may exert an endocrine effect on
breast tissue, and interaction with oestrogen may promote breast
cancer progression after malignant transformation. Clinically
useful markers of increased risk to breast cancer would result if
these findings are confirmed in further studies on cellular and
serum markers ofoestradiol and IGF activity.
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